ArticleAnnals of surgical oncology2026
Cytoreductive Nephrectomy and Thrombectomy for Metastatic Renal Cell Carcinoma with Venous Tumor Thrombus: Experience from a High-Volume Center.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Refining Risk Stratification in Upper Tract Urothelial Carcinoma-The 2-cm Tumor Size Threshold.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Reconsidering Supraclavicular Lymph Node Metastasis in Esophageal Cancer: Implications for Staging and Treatment Selection in the Immunotherapy Era.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeFor metastatic renal cell carcinoma (mRCC) with venous tumor thrombus (TT), the role of cytoreductive nephrectomy (CN) remains controversial, particularly in the targeted-immunotherapy era, and East-Asian data are limited.
methodsThis study retrospectively included 160 East-Asian patients with mRCC with TT who underwent CN and thrombectomy from January 2014 to January 2025. Overall survival (OS) was the primary endpoint. Kaplan-Meier and Cox regression analyses identified prognostic factors. Variables with a p‑value < 0.1 in the univariate analysis were entered into the multivariate analysis. A two‑sided p‑value < 0.05 was considered statistically significant.
resultsMedian follow-up was 35 months; median OS was 41 months. Multivariate analysis identified four independent risk factors for poor OS: sarcomatoid differentiation (p < 0.001), serious postoperative complications (p < 0.001), rhabdoid differentiation (p = 0.004), and pathologic lymph node metastasis (p = 0.005). Mayo level was not significantly associated with OS. Robotic surgery demonstrated superior perioperative outcomes to open surgery, although baseline characteristics between the two groups were not comparable.
conclusionsAcceptable long-term oncologic outcomes are achievable when CN and thrombectomy are performed in carefully selected surgical patients with mRCC and venous TT. Sarcomatoid differentiation, rhabdoid differentiation, pathologic lymph node metastasis, and postoperative serious complications are independent predictors of poor prognosis. To obtain more reliable perioperative outcome data, robotic surgery should be compared with open surgery in larger patient populations. Multidisciplinary evaluation and centralization of care at high‑volume centers are strongly encouraged.
Indexed as
Identifiers
42732019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.